BRPI0608074A2 - derivados de oxa-diaza-espiro-[5.5]-undecanona substituìdos e uso como antagonistas da neurocinina do mesmo - Google Patents
derivados de oxa-diaza-espiro-[5.5]-undecanona substituìdos e uso como antagonistas da neurocinina do mesmoInfo
- Publication number
- BRPI0608074A2 BRPI0608074A2 BRPI0608074-0A BRPI0608074A BRPI0608074A2 BR PI0608074 A2 BRPI0608074 A2 BR PI0608074A2 BR PI0608074 A BRPI0608074 A BR PI0608074A BR PI0608074 A2 BRPI0608074 A2 BR PI0608074A2
- Authority
- BR
- Brazil
- Prior art keywords
- antagonist activity
- diaza
- undecanone
- combined
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Pulmonology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Biophysics (AREA)
- Pain & Pain Management (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
DERIVADOS DE OXA-DIAZA-ESPIRO-[5.5]-UNDECANONA SUBSTITUIDOS E USO COMO ANTAGONISTAS DA NEUROCININA DO MESMO. A presente invenção refere-se a derivados de oxa-diaza-espiro[5.5]-undecanona substituidos tendo atividade antagonista de neurocinina, em particular uma atividade antagonista de NK~ 1~, uma atividade antagonista de NK~ 3~, uma atividade antagonista de NK~ 1~/NK~ 2~ combinada e uma atividade antagonista de NK~ 1~/NK~ 2~/NK~ 3~ combinada, sua preparação, composições compreendendo os mesmos e seu uso como um medicamento, em particular para o tratamento e/ou profilaxia de esquizofrenia, êmese, ansiedade e depressão, síndrome do intestino irritável (IBS), distúrbios do ritmo circadiano, pré-eclãmpsia, nonicepçáo, dor, em particular dor visceral e neuropática, pancreatite, inflamação neurogênica, asma, doença pulmonar obstrutiva crónica (COPD) e distúrbios da micção tais como incontinência urinária. Os compostos de acordo com a invenção podem ser representados pela Fórmula geral (1) e compreendem os sais de adição de ácido ou base farmaceuticamente aceitáveis dos mesmos, as formas estereoquimicamente isoméricas dos mesmos, a forma N-óxido dos mesmos e pró-fármacos dos mesmos, em que todos os substituintes são definidos como na reivindicação 1.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05101657 | 2005-03-03 | ||
| PCT/EP2006/060419 WO2006094934A1 (en) | 2005-03-03 | 2006-03-03 | Substituted oxa-diaza-spiro-[5.5]-undecanone derivatives and their use as neurokinin antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0608074A2 true BRPI0608074A2 (pt) | 2009-11-03 |
Family
ID=34938877
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0608074-0A BRPI0608074A2 (pt) | 2005-03-03 | 2006-03-03 | derivados de oxa-diaza-espiro-[5.5]-undecanona substituìdos e uso como antagonistas da neurocinina do mesmo |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8138334B2 (pt) |
| EP (1) | EP1874783B1 (pt) |
| JP (1) | JP5094422B2 (pt) |
| KR (1) | KR101355064B1 (pt) |
| CN (1) | CN101133064B (pt) |
| AT (1) | ATE469159T1 (pt) |
| AU (1) | AU2006222061B2 (pt) |
| BR (1) | BRPI0608074A2 (pt) |
| CA (1) | CA2598530C (pt) |
| DE (1) | DE602006014531D1 (pt) |
| EA (1) | EA012421B1 (pt) |
| ES (1) | ES2346147T3 (pt) |
| MX (1) | MX2007010728A (pt) |
| NZ (1) | NZ556629A (pt) |
| WO (1) | WO2006094934A1 (pt) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8349852B2 (en) | 2009-01-13 | 2013-01-08 | Novartis Ag | Quinazolinone derivatives useful as vanilloid antagonists |
| JP2013518085A (ja) | 2010-02-01 | 2013-05-20 | ノバルティス アーゲー | ＣＲＦ−１受容体アンタゴニストとしてのピラゾロ［５，１ｂ］オキサゾール誘導体 |
| AR080056A1 (es) | 2010-02-01 | 2012-03-07 | Novartis Ag | Derivados de ciclohexil-amida como antagonistas de los receptores de crf |
| JP5748777B2 (ja) | 2010-02-02 | 2015-07-15 | ノバルティス アーゲー | Ｃｒｆ受容体アンタゴニストとしてのシクロヘキシルアミド誘導体 |
| EP3915560A1 (en) | 2014-06-25 | 2021-12-01 | Emory University | Methods of managing conditioned fear with neurokinin receptor antagonists |
| KR101579688B1 (ko) | 2014-07-08 | 2015-12-24 | 재단법인 전남생물산업진흥원 | 좁쌀풀 추출물을 유효성분으로 함유하는 과민성 대장증후군에 의한 내장 통증 억제예방 또는 치료용 약학 조성물 |
| EP3704271B1 (en) | 2017-11-02 | 2026-01-28 | California Institute of Technology | Neurokinin antagonists and uses thereof |
| WO2020048826A1 (en) | 2018-09-03 | 2020-03-12 | Bayer Aktiengesellschaft | 5-substituted 1-oxa-3,9-diazaspiro[5.5]undecan-2-one compounds |
| WO2020048827A1 (en) | 2018-09-03 | 2020-03-12 | Bayer Aktiengesellschaft | 1, 3, 9-triazaspiro[5.5] undecan-2-one compounds |
| WO2020048828A1 (en) | 2018-09-03 | 2020-03-12 | Bayer Pharma Aktiengesellschaft | 5-heteroaryl-3,9-diazaspiro[5.5]undecane compounds |
| US20230346792A1 (en) * | 2020-07-18 | 2023-11-02 | Hoth Therapeutics, Inc. | Compositions and methods for treating lung inflammation |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5403593A (en) | 1991-03-04 | 1995-04-04 | Sandoz Ltd. | Melt granulated compositions for preparing sustained release dosage forms |
| GB9109862D0 (en) | 1991-05-08 | 1991-07-03 | Beecham Lab Sa | Pharmaceutical formulations |
| TW429256B (en) | 1995-12-27 | 2001-04-11 | Janssen Pharmaceutica Nv | 1-(1,2-disubstituted piperidinyl)-4-(benzimidazolyl- and imidazopyridinyl)-piperidine derivatives |
| TW382017B (en) | 1995-12-27 | 2000-02-11 | Janssen Pharmaceutica Nv | 1-(1,2-disubstituted piperidinyl)-4-(fused imidazole)-piperidine derivatives |
| TW531537B (en) * | 1995-12-27 | 2003-05-11 | Janssen Pharmaceutica Nv | 1-(1,2-disubstituted piperidinyl)-4-substituted piperidine derivatives |
| TR200000529T2 (tr) | 1997-08-29 | 2000-08-21 | Dsm N.V. | İçinde eksipiyan olmayan granüller |
| US6482829B2 (en) | 2000-06-08 | 2002-11-19 | Hoffmann-La Roche Inc. | Substituted heterocyclic siprodecane compound active as an antagonist of neurokinin 1 receptor |
| JP4101053B2 (ja) * | 2000-08-10 | 2008-06-11 | 田辺三菱製薬株式会社 | プロリン誘導体及びその医薬用途 |
| CN1264847C (zh) * | 2001-05-14 | 2006-07-19 | 弗·哈夫曼-拉罗切有限公司 | 1－氧杂－3,9－二氮杂－螺[5.5]十一－2－酮衍生物及其作为神经激肽受体拮抗剂的用途 |
| WO2003057698A2 (en) * | 2001-12-28 | 2003-07-17 | Acadia Pharmaceuticals, Inc. | Spiroazacyclic compounds as monoamine receptor modulators |
| MY141736A (en) * | 2002-10-08 | 2010-06-15 | Elanco Animal Health Ireland | Substituted 1,4-di-piperidin-4-yi-piperazine derivatives and their use as neurokinin antagonists |
| WO2004110415A2 (en) * | 2003-06-10 | 2004-12-23 | Janssen Pharmaceutica N.V. | Substituted 1, 4-di-piperidin-4-yl-piperazine derivative combined with an opioid analgesic and their use for the treatment of pain and side-effects associated with opioid-based treatments |
| RU2006132465A (ru) * | 2004-02-10 | 2008-03-20 | Ф.Хоффманн-Ля Рош Аг (Ch) | Модуляторы хемокинового рецептора ccr5 |
-
2006
- 2006-03-03 DE DE602006014531T patent/DE602006014531D1/de not_active Expired - Lifetime
- 2006-03-03 NZ NZ556629A patent/NZ556629A/en not_active IP Right Cessation
- 2006-03-03 AU AU2006222061A patent/AU2006222061B2/en not_active Ceased
- 2006-03-03 CN CN2006800066125A patent/CN101133064B/zh not_active Expired - Fee Related
- 2006-03-03 US US11/913,890 patent/US8138334B2/en not_active Expired - Fee Related
- 2006-03-03 EA EA200701879A patent/EA012421B1/ru not_active IP Right Cessation
- 2006-03-03 WO PCT/EP2006/060419 patent/WO2006094934A1/en not_active Ceased
- 2006-03-03 ES ES06708618T patent/ES2346147T3/es not_active Expired - Lifetime
- 2006-03-03 CA CA2598530A patent/CA2598530C/en not_active Expired - Fee Related
- 2006-03-03 BR BRPI0608074-0A patent/BRPI0608074A2/pt not_active IP Right Cessation
- 2006-03-03 EP EP06708618A patent/EP1874783B1/en not_active Expired - Lifetime
- 2006-03-03 MX MX2007010728A patent/MX2007010728A/es active IP Right Grant
- 2006-03-03 JP JP2007557517A patent/JP5094422B2/ja not_active Expired - Fee Related
- 2006-03-03 AT AT06708618T patent/ATE469159T1/de not_active IP Right Cessation
- 2006-03-03 KR KR1020077020930A patent/KR101355064B1/ko not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006094934A1 (en) | 2006-09-14 |
| ATE469159T1 (de) | 2010-06-15 |
| JP2008531659A (ja) | 2008-08-14 |
| DE602006014531D1 (de) | 2010-07-08 |
| EP1874783A1 (en) | 2008-01-09 |
| EA012421B1 (ru) | 2009-10-30 |
| KR101355064B1 (ko) | 2014-01-24 |
| CA2598530C (en) | 2014-12-16 |
| ES2346147T3 (es) | 2010-10-11 |
| EP1874783B1 (en) | 2010-05-26 |
| KR20070113224A (ko) | 2007-11-28 |
| MX2007010728A (es) | 2007-10-12 |
| NZ556629A (en) | 2010-04-30 |
| US8138334B2 (en) | 2012-03-20 |
| US20100292228A1 (en) | 2010-11-18 |
| CA2598530A1 (en) | 2006-09-14 |
| AU2006222061B2 (en) | 2011-04-28 |
| JP5094422B2 (ja) | 2012-12-12 |
| EA200701879A1 (ru) | 2008-02-28 |
| CN101133064B (zh) | 2011-02-23 |
| WO2006094934A8 (en) | 2006-12-07 |
| CN101133064A (zh) | 2008-02-27 |
| AU2006222061A1 (en) | 2006-09-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021022099A2 (pt) | Derivados de amino quinazolina como inibidores de p2x3 | |
| BRPI0509720A (pt) | derivados de 4-alquil- e 4-alcanoil-piperidina substituìda e seu uso como antagonistas de neurocinina | |
| BR112015012366A8 (pt) | antagonistas de cxcr7, uso dos mesmos, composição farmacêutica, bem como métodos para detectar níveis elevados de cxcr7 em uma amostra e para imagear um tumor, órgão, ou tecido | |
| BR112014001801A2 (pt) | indazóis | |
| BRPI0508461B8 (pt) | diaminopirimidinas, seus usos, e composição farmacêutica | |
| WO2007127635A3 (en) | Diketo-piperazine and piperidine derivatives as antiviral agents | |
| TW200604198A (en) | Substituted diaza-spiro-[4.5]-decane derivatives and their use as neurokinin antagonists | |
| ATE538100T1 (de) | Aminotetrahydroindazoloessigsäuren | |
| BR112014028954A2 (pt) | amidas de n-piridinila substituídas no anel como inibidores da quinase | |
| BR0317658A (pt) | Derivados de 1-piperidin-4-il-4-pirrolidin-3-il-piperazina substituìda e seu emprego como antagonistas de neuroquinina | |
| BRPI0608074A2 (pt) | derivados de oxa-diaza-espiro-[5.5]-undecanona substituìdos e uso como antagonistas da neurocinina do mesmo | |
| WO2010091104A8 (en) | Glucosylceramide synthase inhibitors | |
| MX350862B (es) | Acidos de piperidinil naftilacetico. | |
| TW200716120A (en) | Pyrazolo-pyrimidine derivatives as mGluR2 antagonists | |
| WO2010018112A3 (en) | Monoaryl aminotetralines | |
| BR112015025804A2 (pt) | derivados de glutarimida, uso dos mesmos, composição farmacêutica com base neles e métodos para a produção de derivados de glutarimida | |
| MY142090A (en) | Substituted diaza-spiro-[5.5]-undecane derivatives and their use as neurokinin antagonists | |
| MX2009005507A (es) | Derivados de espiro-piperidina. | |
| BR112021020279A2 (pt) | Derivados de piridopirimidinas como inibidores de p2x3 | |
| BRPI0511424A (pt) | composto, composição farmacêutica, uso de um composto, método de tratamento ou profilaxia de doenças inflamatórias, e, processo para a preparação de um composto | |
| BR112014016007A8 (pt) | derivados de quinazolinona como inibidores de vhc | |
| EA201070927A1 (ru) | Двойные фармакофоры-pde4-мускариновые антагонисты | |
| MX2023005801A (es) | Derivados de ftalazina como inhibidores de purinoceptor 3 de p2x (p2x3). | |
| MX2009005504A (es) | Derivados de espiro piperidina como antagonistas del receptor via. | |
| EA200701898A1 (ru) | Производные диаза-спиро-[4.4]-нонана в качестве антагонистов нейрокинина (nk1) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 11A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |